Error message

EDS Server Issue
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: eCollection Cited Medium: Print ISSN: 2352-3964 (Print) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
    • Subject Terms:
    • Abstract:
      Background: Hepatocellular carcinoma (HCC) is prevalent worldwide and early diagnosis of HCC is critical for effective treatment and optimal prognosis.
      Methods: Serum was screened first by immunoproteomic analysis for HCC-related tumor associated antigens (TAAs). Selected TAAs were clinically evaluated retrospectively in patients with HCC, liver cirrhosis, chronic hepatitis and healthy controls. Levels of autoantibody to the selected TAAs were measured by protein microarrays containing protein antigens of the candidate TAAs. Analyses were done by using receiver operating characteristics (ROC) to calculate diagnostic accuracy.
      Findings: Twenty-two candidate TAAs were assessed by protein microarray analysis in 914 participants with serum α-fetoprotein (AFP) available. Twelve candidate TAAs were statistically different in signal intensity between HCC and controls. Among them, CENPF, HSP60 and IMP-2 showed AUC (area under the curve) values of 0.826, 0.764 and 0.796 respectively for early HCC. The highest prevalence of autoantibody positivity was observed in HCC cases with BCLC tumor stage A, well-differentiated histology and Child-Pugh grade C. Specifically, 73.6% or 79.3% cases of early HCC with negative AFP were positive for autoantibody to CENPF or HSP60.
      Interpretation: Tumor-associated autoimmune reactions may be triggered by early stage HCCs. Measurement of serum autoantibody to TAAs may be complementary to AFP measurements and improve diagnosis of early HCC.
    • Comments:
      Comment in: EBioMedicine. 2015 May;2(5):370-1. (PMID: 26137579)
    • References:
      J Ovarian Res. 2014 Mar 11;7:30. (PMID: 24618330)
      Lancet Oncol. 2009 Nov;10(11):1111-8. (PMID: 19880065)
      Cancer Epidemiol. 2012 Feb;36(1):82-8. (PMID: 22018955)
      J Immunol Res. 2014;2014:574981. (PMID: 25143958)
      Autoimmune Dis. 2012;2012:486069. (PMID: 23056925)
      Hepatol Int. 2014 Apr;8(2):250-9. (PMID: 26202506)
      J Proteome Res. 2008 Feb;7(2):611-20. (PMID: 18161940)
      Mol Clin Oncol. 2013 Jul;1(4):593-598. (PMID: 24649215)
      Am J Gastroenterol. 2014 Jan;109(1):36-45. (PMID: 24296751)
      Int J Cancer. 2015 May 15;136(10):2243-52. (PMID: 24615018)
      Autoimmun Rev. 2002 May;1(3):146-53. (PMID: 12849008)
      Am J Gastroenterol. 2006 Mar;101(3):524-32. (PMID: 16542289)
      FEBS J. 2011 Dec;278(24):4845-59. (PMID: 21973086)
      Semin Oncol. 2012 Aug;39(4):410-33. (PMID: 22846859)
      Proteomics Clin Appl. 2007 Mar;1(3):336-42. (PMID: 21136683)
      Proteomics. 2005 Apr;5(6):1686-92. (PMID: 15800975)
      Hepatology. 2009 Sep;50(3):661-2. (PMID: 19714720)
      Clin Exp Immunol. 2010 May;160(2):215-22. (PMID: 20030668)
      J Proteomics. 2013 Dec 6;94:346-58. (PMID: 24125732)
      Biochem Biophys Res Commun. 2013 Jul 12;436(4):711-8. (PMID: 23791740)
      Curr Pharm Des. 2013;19(3):452-7. (PMID: 22920896)
      Mol Cell Proteomics. 2006 Oct;5(10):1745-59. (PMID: 16733262)
      World J Gastroenterol. 2010 Jan 28;16(4):418-24. (PMID: 20101765)
      FEBS J. 2009 Dec;276(23):6880-904. (PMID: 19860826)
      Lancet Oncol. 2012 Aug;13(8):817-26. (PMID: 22738799)
      Semin Oncol. 2012 Aug;39(4):399-409. (PMID: 22846858)
      Hepatology. 2005 Nov;42(5):1208-36. (PMID: 16250051)
      J Natl Cancer Inst. 2008 May 21;100(10):698-711. (PMID: 18477802)
      Nat Med. 2002 Mar;8(3):295-301. (PMID: 11875502)
    • Contributed Indexing:
      Keywords: Autoantibody; Early diagnosis; Hepatocellular carcinoma; Serological marker; Tumor associated antigen
      Note: Original DateCompleted: 20150703
    • Accession Number:
      0 (Antigens, Neoplasm)
      0 (Autoantibodies)
    • Publication Date:
      Date Created: 20150703 Date Completed: 20160809 Latest Revision: 20181113
    • Publication Date:
      20201020
    • Accession Number:
      PMC4486196
    • Accession Number:
      10.1016/j.ebiom.2015.03.010
    • Accession Number:
      26137588
  • Citations
    • ABNT:
      HONG, Y. et al. An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. EBioMedicine, [s. l.], v. 2, n. 5, p. 438–446, 2015. DOI 10.1016/j.ebiom.2015.03.010. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=26137588. Acesso em: 28 out. 2020.
    • AMA:
      Hong Y, Long J, Li H, et al. An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. EBioMedicine. 2015;2(5):438-446. doi:10.1016/j.ebiom.2015.03.010
    • APA:
      Hong, Y., Long, J., Li, H., Chen, S., Liu, Q., Zhang, B., He, X., Wang, Y., Li, H., Li, Y., Zhang, T., Lu, C., Yan, H., Zhang, M., Li, Q., Cao, B., Bai, Z., Wang, J., Zhang, Z., … Huang, J. (2015). An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. EBioMedicine, 2(5), 438–446. https://doi.org/10.1016/j.ebiom.2015.03.010
    • Chicago/Turabian: Author-Date:
      Hong, Yu, Jiang Long, Hai Li, Shuhong Chen, Qiqi Liu, Bei Zhang, Xiaomin He, et al. 2015. “An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.” EBioMedicine 2 (5): 438–46. doi:10.1016/j.ebiom.2015.03.010.
    • Harvard:
      Hong, Y. et al. (2015) ‘An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma’, EBioMedicine, 2(5), pp. 438–446. doi: 10.1016/j.ebiom.2015.03.010.
    • Harvard: Australian:
      Hong, Y, Long, J, Li, Hai, Chen, S, Liu, Q, Zhang, B, He, X, Wang, Y, Li, Hongyi, Li, Y, Zhang, T, Lu, C, Yan, H, Zhang, M, Li, Q, Cao, B, Bai, Z, Wang, J, Zhang, Z, Zhu, S, Zheng, J, Ou, X, Ma, H, Jia, J, You, H, Wang, S & Huang, J 2015, ‘An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma’, EBioMedicine, vol. 2, no. 5, pp. 438–446, viewed 28 October 2020, .
    • MLA:
      Hong, Yu, et al. “An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.” EBioMedicine, vol. 2, no. 5, Mar. 2015, pp. 438–446. EBSCOhost, doi:10.1016/j.ebiom.2015.03.010.
    • Chicago/Turabian: Humanities:
      Hong, Yu, Jiang Long, Hai Li, Shuhong Chen, Qiqi Liu, Bei Zhang, Xiaomin He, et al. “An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.” EBioMedicine 2, no. 5 (March 13, 2015): 438–46. doi:10.1016/j.ebiom.2015.03.010.
    • Vancouver/ICMJE:
      Hong Y, Long J, Li H, Chen S, Liu Q, Zhang B, et al. An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. EBioMedicine [Internet]. 2015 Mar 13 [cited 2020 Oct 28];2(5):438–46. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=26137588